Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Theranostics|September 18, 2025
Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.
European Journal of Neurology|September 26, 2025
Neurological Examinations of Patients Initially Diagnosed With Wild-Type Transthyretin Amyloidosis (wtATTR)Jakob Stögbauer, Niklas Kämpfer, Ingrid Kindermann, et al.
Diagnostics (Basel, Switzerland)|October 16, 2024
Cutting the Gordian Knot: Rare Presentation of Nodular Fasciitis as Supraclavicular Swelling with Muscular Involvement in 68Ga-FAPI-PET/CTLukas A Brust, Madeleine Höh, Maximilian Linxweiler, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 23, 2024
[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysisFlorian Rosar, Caroline Burgard, Elena Larsen, et al.
Scientific Reports|May 17, 2024
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLTFlorian Rosar, Caroline Burgard, Scott David, et al.
Clinical Nuclear Medicine|March 2, 2022
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CTFlorian Rosar, Mark Bartholomä, Stephan Maus, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
Journal of Clinical Medicine|September 9, 2022
Primary Staging of Prostate Cancer Patients with [18F]PSMA-1007 PET/CT Compared with [68Ga]Ga-PSMA-11 PET/CTManuela A Hoffmann, Jonas Müller-Hübenthal, Florian Rosar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2020
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamideFlorian Rosar, Sebastian Dewes, Martin Ries, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2025
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)Moritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Pageof 10